Acute Renal Failure Clinical Trial
Official title:
A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)
Acute renal failure, now referred to as acute kidney injury, is common in intensive care
unit patients, contributes to high morbidity and mortality, and has no proven interventions
with benefit once established. In addition to supportive care, these patients frequently
receive diuretic therapy, most commonly furosemide.
Prior trials showed no impact of furosemide on clinical outcomes and perhaps harm, however,
these trials suffered from numerous limitations and lack applicability to modern intensive
care unit patients. As a result, there appears a disconnect between clinical practice and
available evidence. Survey data supports the view of clinical equipoise for use of
furosemide in intensive care unit patients with early acute kidney injury. Moreover, these
data also confirm there is an urgent need for higher quality and more definitive evidence
from randomized trial on furosemide use in early acute kidney injury.
Accordingly, the investigators propose to conduct a pilot phase II randomized, blinded,
placebo-controlled trial comparing furosemide to placebo in ICU patients with early acute
kidney injury.
The specific aims of this study are:
1. To compare the efficacy and safety of a continuous infusion of furosemide versus
placebo titrated to the physiology parameter of urine output in early acute kidney
injury on the primary outcome of progression in severity of kidney injury in intensive
care unit patients with early AKI and stratified by the presence of sepsis.
2. To evaluate selected secondary endpoints on the impact of furosemide versus placebo,
specifically: fluid balance goals; electrolyte and acid-base balance; the need for
renal replacement therapy (i.e. dialysis); total duration of acute kidney injury; the
rate of renal recovery; and mortality.
3. To compare the impact of furosemide versus placebo on the trajectory of serum and
urinary biomarkers (neutrophil gelatinase-associated lipocalin [NGAL], interleukin-18
[IL-18]) and evaluate whether these biomarkers perform superior to conventional
measures (creatinine, urea) for monitoring the progression of kidney injury and the
prediction of outcome.
This trial represents part of a larger initiative aimed towards expanding our understanding
of the treatment of acute kidney injury in intensive care unit patients and evaluating
interventions that may potentially reduce kidney injury and improve clinical outcomes.
Study Design, Setting and Patient Population
This is a phase II multi-centre, randomized, blinded, placebo-controlled trial of ICU
patients with early AKI with randomization stratified by sepsis. All critically ill patients
admitted to the participating ICUs will be screened for eligibility.
Operational Definitions
1. Acute kidney injury (AKI) - The operational definition for early AKI will be defined and
classified according to the RIFLE criteria (and modified AKIN). The presence of early AKI
will be defined by the RIFLE class - RISK: an abrupt (within 48hr) reduction in kidney
function characterized by an relative increase in serum creatinine of >50% (1.5 fold) or
>26.5 mcmol/L from baseline or a reduction in urine output of ≤0.5 mL/kg/hr for >6 hours.
Trial Protocol
Description of Study Flow
Patients will be identified in the ICU by daily surveillance of admitted patients by the PI
and/or research coordinator or when identified by the treating ICU physician. Each patient's
eligibility will be verified by use of a one-page checklist that summarizes the inclusion
and exclusion criteria. This checklist will be included in the standardized case-report form
(CRF).
Study Intervention
Following obtainment of consent, patients will be commenced on a continuous infusion of
either the intervention (furosemide) or identical placebo (0.9% NaCl). The study protocol
for administration of furosemide by continuous infusion is adapted from the phase I study by
Ostermann et al. The study infusion bag will contain 2000mg of furosemide in 500mL of
0.9%NaCl for a final concentration of 4mg/mL. The continuous infusion will be titrated to
achieve a target urine output in the range of 1.0-2.0 mL/kg/hr. Each patient will be
administered a loading dose of 0.4 mg/kg as a separate infusion bag followed by a continuous
infusion commenced at a dose of 0.0125 ml/kg/hr. The maximum infusion rate will be
0.125ml/kg/hr. The urine output will be assessed hourly. If the target urine output has been
achieved, then the current infusion rate will be continued. If the target urine output has
not been achieved, the dose will be increased to the next infusion rate in the algorithm. If
the urine output is too brisk (>2mL/kg/hr), the dose will be maintained unless any of the
following criteria are fulfilled: decrease in mean arterial pressure <65 AND/OR addition of
or an increase in vasoactive requirements of ≥20% to achieve goal mean arterial pressure OR
central venous pressure <8 cmH2O OR central venous oxygen saturation <60% OR a cardiac index
<2.0L/min/1.73m2 (if measured). If any of these criteria are achieved, the dose will be
decreased to the next lower infusion rate in the algorithm. If any of the aforementioned
criteria have been fulfilled AND urine output remains >2mL/kg/hr for 2 consecutive hours
despite the lowest infusion rate, the treatment will be discontinued for 1 hour then resumed
at the lowest infusion rate. The fulfillment of these criteria will be brought to the
attention of the consultant ICU physician for review. At any time during the trial, if the
responsible ICU physician believes that diuretics are urgently indicated (pulmonary edema),
diuretics can be administered and this event will be documented.
All other aspects of patient management within the parameters outlined (methods of fluid
resuscitation, choice of fluids, vasoactive therapy, choice of vasoactive therapy, adjuvant
therapies such as hrAPC, intensive insulin therapy, will be at the discretion of the
consultant ICU physician.
The study drug infusion will be continued until any one of the following events occur:
1. the patient is initiated on RRT;
2. the patient dies;
3. the patient is discharged from the ICU;
4. the patient recovers kidney function; or
5. the patient develops a recognized adverse reaction potentially related to the study
infusion.
Methods of Randomization
The randomization sequence will be created at a single central location at the University of
Alberta Hospital (EPICORE Centre). The sequence will be stratified by the presence of a
diagnosis of sepsis.
Data Collection
Detailed clinical, physiologic, laboratory and outcome data will be collected. Data will be
collected each day on whether the primary endpoint (progression of AKI) has occurred, for
evidence of any secondary endpoints and criteria for trial discontinuation. Plasma and urine
will be collected for biomarkers studies. Any study protocol violations will be recorded.
The adjudication of protocol violations will be determined by a study investigator blinded
to the treatment allocation.
Proposed Follow-up
The investigators plan to follow all patients to determine the duration of AKI, continued
need for RRT, renal recovery and mortality until death or discharge from hospital and at 30,
60 and 90-days after randomization.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01946113 -
Mineral-Homeostasis in Continuous Renal Replacement Therapy
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Withdrawn |
NCT00993733 -
Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care
|
N/A | |
Completed |
NCT00120263 -
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
|
N/A | |
Completed |
NCT04799600 -
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
|
||
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
Recruiting |
NCT05282732 -
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
|
||
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01979042 -
Urinary Markers for Unilateral Kidney Obstruction
|
N/A | |
Completed |
NCT01280617 -
Low Dose Thymoglobin in Renal Transplant Patients
|
N/A | |
Completed |
NCT00780351 -
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|
N/A | |
Completed |
NCT00971971 -
Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
|
N/A | |
Completed |
NCT00076219 -
Acute Renal Failure Trial Network (ATN) Study
|
Phase 3 | |
Recruiting |
NCT04599569 -
Influence of Renal Replacement TherApy on Indirect Calorimetry
|
||
Completed |
NCT03727204 -
Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
|
||
Completed |
NCT06005896 -
A Clinical Model for Dialysis Discontinuation in AKI
|
||
Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 | |
Completed |
NCT03004950 -
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
|
||
Recruiting |
NCT04682236 -
Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation
|